Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-trace').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f06ecd1dfd4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-code').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-context').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f06ecd1dfd4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f06ecd1dfd4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 33233,
		&#039;title&#039; =&gt; &#039;The high price of Big Pharma greed -Leena Menghaney&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;
&lt;br /&gt;
Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;
&lt;br /&gt;
After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;
&lt;br /&gt;
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;
&lt;br /&gt;
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;the-high-price-of-big-pharma-greed-leena-menghaney-4681323&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4681323,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 33233,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;&lt;br /&gt;Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;&lt;br /&gt;After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;&lt;br /&gt;Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;&lt;br /&gt;For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;&lt;br /&gt;In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot; title=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 33233,
	&#039;title&#039; =&gt; &#039;The high price of Big Pharma greed -Leena Menghaney&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;
&lt;br /&gt;
Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;
&lt;br /&gt;
After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;
&lt;br /&gt;
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;
&lt;br /&gt;
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;the-high-price-of-big-pharma-greed-leena-menghaney-4681323&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4681323,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 33233
$metaTitle = &#039;LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs&#039;
$metaDesc = &#039;
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;&lt;br /&gt;Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;&lt;br /&gt;After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;&lt;br /&gt;Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;&lt;br /&gt;For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;&lt;br /&gt;In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot; title=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney | Im4change.org</title>
    <meta name="description" content="
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>The high price of Big Pharma greed -Leena Menghaney</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br />In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br /><br />Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br /><br />After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br /><br />Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br /><br />For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br /><br />In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br /><br />Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece" title="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-trace').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f06ecd1dfd4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-code').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-context').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f06ecd1dfd4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f06ecd1dfd4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 33233,
		&#039;title&#039; =&gt; &#039;The high price of Big Pharma greed -Leena Menghaney&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;
&lt;br /&gt;
Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;
&lt;br /&gt;
After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;
&lt;br /&gt;
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;
&lt;br /&gt;
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;the-high-price-of-big-pharma-greed-leena-menghaney-4681323&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4681323,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 33233,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;&lt;br /&gt;Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;&lt;br /&gt;After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;&lt;br /&gt;Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;&lt;br /&gt;For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;&lt;br /&gt;In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot; title=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 33233,
	&#039;title&#039; =&gt; &#039;The high price of Big Pharma greed -Leena Menghaney&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;
&lt;br /&gt;
Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;
&lt;br /&gt;
After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;
&lt;br /&gt;
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;
&lt;br /&gt;
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;the-high-price-of-big-pharma-greed-leena-menghaney-4681323&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4681323,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 33233
$metaTitle = &#039;LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs&#039;
$metaDesc = &#039;
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;&lt;br /&gt;Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;&lt;br /&gt;After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;&lt;br /&gt;Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;&lt;br /&gt;For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;&lt;br /&gt;In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot; title=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney | Im4change.org</title>
    <meta name="description" content="
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>The high price of Big Pharma greed -Leena Menghaney</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br />In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br /><br />Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br /><br />After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br /><br />Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br /><br />For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br /><br />In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br /><br />Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece" title="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-trace').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f06ecd1dfd4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-code').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f06ecd1dfd4-context').style.display = (document.getElementById('cakeErr67f06ecd1dfd4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f06ecd1dfd4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f06ecd1dfd4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 33233,
		&#039;title&#039; =&gt; &#039;The high price of Big Pharma greed -Leena Menghaney&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;
&lt;br /&gt;
Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;
&lt;br /&gt;
After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;
&lt;br /&gt;
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;
&lt;br /&gt;
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;the-high-price-of-big-pharma-greed-leena-menghaney-4681323&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4681323,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 33233,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;&lt;br /&gt;Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;&lt;br /&gt;After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;&lt;br /&gt;Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;&lt;br /&gt;For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;&lt;br /&gt;In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot; title=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 33233,
	&#039;title&#039; =&gt; &#039;The high price of Big Pharma greed -Leena Menghaney&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;
&lt;br /&gt;
Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;
&lt;br /&gt;
After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;
&lt;br /&gt;
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;
&lt;br /&gt;
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;the-high-price-of-big-pharma-greed-leena-menghaney-4681323&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4681323,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 33233
$metaTitle = &#039;LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs&#039;
$metaDesc = &#039;
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp;amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.&lt;br /&gt;&lt;br /&gt;Roche effectively embroiled India&amp;rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.&lt;br /&gt;&lt;br /&gt;After a wait of over three years, the Delhi High Court&amp;rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.&lt;br /&gt;&lt;br /&gt;Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.&lt;br /&gt;&lt;br /&gt;For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&amp;rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.&lt;br /&gt;&lt;br /&gt;In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&amp;rsquo;s charged U.S. $38,365 for Trastuzumab.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot; title=&quot;http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece&quot;&gt;click here&lt;/a&gt; to read more.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/the-high-price-of-big-pharma-greed-leena-menghaney-4681323.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney | Im4change.org</title>
    <meta name="description" content="
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>The high price of Big Pharma greed -Leena Menghaney</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br />In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br /><br />Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br /><br />After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br /><br />Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br /><br />For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br /><br />In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br /><br />Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece" title="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 33233,
		'title' => 'The high price of Big Pharma greed -Leena Menghaney',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu<br />
<br />
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br />
<br />
Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br />
<br />
After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br />
<br />
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br />
<br />
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br />
<br />
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br />
<br />
Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.
</div>',
		'credit_writer' => 'The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'the-high-price-of-big-pharma-greed-leena-menghaney-4681323',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4681323,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 33233,
	'metaTitle' => 'LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney',
	'metaKeywords' => 'Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs',
	'metaDesc' => '
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...',
	'disp' => '<div align="justify">-The Hindu<br /><br />In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br /><br />Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br /><br />After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br /><br />Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br /><br />For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br /><br />In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br /><br />Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece" title="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 33233,
	'title' => 'The high price of Big Pharma greed -Leena Menghaney',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu<br />
<br />
In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br />
<br />
Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br />
<br />
After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br />
<br />
Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br />
<br />
For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br />
<br />
In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br />
<br />
Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.
</div>',
	'credit_writer' => 'The Hindu, 5 March, 2017, http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'the-high-price-of-big-pharma-greed-leena-menghaney-4681323',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4681323,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 33233
$metaTitle = 'LATEST NEWS UPDATES | The high price of Big Pharma greed -Leena Menghaney'
$metaKeywords = 'Access to Health,Access to Healthcare,Public Health,Medicine Prices,Access to Medicines,Intellectual Property Rights,IPRs'
$metaDesc = '
-The Hindu

In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit...'
$disp = '<div align="justify">-The Hindu<br /><br />In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food &amp; Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer.<br /><br />Roche effectively embroiled India&rsquo;s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors.<br /><br />After a wait of over three years, the Delhi High Court&rsquo;s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab.<br /><br />Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine.<br /><br />For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister&rsquo;s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach.<br /><br />In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche&rsquo;s charged U.S. $38,365 for Trastuzumab.<br /><br />Please <a href="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece" title="http://www.thehindu.com/sci-tech/health/the-high-price-of-big-pharma-greed/article17409267.ece">click here</a> to read more.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

The high price of Big Pharma greed -Leena Menghaney

-The Hindu In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food & Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer. Roche effectively embroiled India’s drug regulatory body and biosimilar producers in a long-drawn, expensive and increasingly complex litigation to try and prevent the marketing of potentially affordable versions of the cancer drug from competitors. The suit was aimed at questioning the ability of the Indian FDA to register biosimilars and made frivolous assertions regarding copyright infringement of its package insert by competitors. After a wait of over three years, the Delhi High Court’s decision last week lifts some of the uncertainty surrounding the sale of the more affordable versions of the breast cancer drug in India. The court ruled that in view of the fact that the appropriate authority has approved the package insert and the drug for all three indications (metastatic breast cancer, early breast cancer and gastric cancer), the competitors should be permitted to sell Trastuzumab. Young women in their thirties being diagnosed with breast cancer benefit from Trastuzumab as it reduces the risk of recurrence. Most patients struggle to pay for their surgery and chemotherapy and Roche was charging a staggering Rs. 10 lakh for 17 cycles of the medicine. For poorer patients, this meant that despite a grant of partial treatment costs under the Prime Minister’s National Relief Fund (PMNRF), patients still fell short of money. Often, poor women diagnosed with breast cancer were not even told about the treatment option. One oncologist described it as being cruel to tell his patient that there was a drug that could potentially save her life but priced out of reach. In South Africa, women like Tobeka Daki, a breast cancer patient who died fighting Roche, were denied a chance of survival, not for medical reasons but because Roche’s charged U.S. $38,365 for Trastuzumab. Please click here to read more.